1 / 21

2 nd Annual Technical Review, Brussels , 21 March 2006

WP 6.1 Pharmainformatics. Work Package 6.1 ‘Pharmainformatics’. 2 nd Annual Technical Review, Brussels , 21 March 2006. WP 6.1 Pharmainformatics. WP 6.1 Pharmainformatics. Team. Johan van der Lei Marissa de Mos Erik van Mulligan. Jordi Mestres Montserrat Cases. Scott Boyer

blaise
Download Presentation

2 nd Annual Technical Review, Brussels , 21 March 2006

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WP 6.1 Pharmainformatics Work Package 6.1‘Pharmainformatics’ 2nd Annual Technical Review, Brussels, 21 March 2006

  2. WP 6.1 Pharmainformatics WP 6.1 Pharmainformatics Team Johan van der Lei Marissa de Mos Erik van Mulligan Jordi Mestres Montserrat Cases Scott Boyer Kristina Hettne (+3 Internal Reviewers) 2nd Annual Technical Review, Brussels, 21 March 2006

  3. WP 6.1 Pharmainformatics WP 6.1 Pharmainformatics Team Meetings & Exchanges • Quarterly project meetings • -two-4 day working meetings • Exchanges • -AZ bioinformatician -> Erasmus to be exposed to MI • -Erasmus clinician -> AZ to work with bioinformatics tools • -IMIM -> AZ to expand chemogenomics methods (planned) 2nd Annual Technical Review, Brussels, 21 March 2006

  4. WP 6.1 Pharmainformatics Objectives • Establish a project that would: • Highlight the benefits of BMI in Drug Discovery • Identify particular challenges of BMI • Demonstrate the benefit of cross-functional collaboration 2nd Annual Technical Review, Brussels, 21 March 2006

  5. WP 6.1 Pharmainformatics WP 6.1 Pharmainformatics Rationale & Approach Information Continuum Pathology Pathway Target Ligand Vocabularies/Ontologies 2nd Annual Technical Review, Brussels, 21 March 2006

  6. WP 6.1 Pharmainformatics Rationale & Approach Information Continuum Pathology Pathway Target Ligand Complex Regional Pain Syndrome (CRPS) Evolution Nuclear Hormone Receptors (NHRs) 2nd Annual Technical Review, Brussels, 21 March 2006

  7. WP 6.1 Pharmainformatics CRPS - Last Review ’Target Identification’ Pathology Pathway Target Ligand Evolution Target Validation - Using BMI 2nd Annual Technical Review, Brussels, 21 March 2006

  8. WP 6.1 Pharmainformatics CRPS - Presently ’Target Identification’ Pathology Pathway Target Ligand Evolution Target Validation - Using BMI 2nd Annual Technical Review, Brussels, 21 March 2006

  9. 10 1 Attrition 100 1 100 1000 Cost ($M) WP 6.1 Pharmainformatics Linear Model of Drug Discovery Target Identification Concept Testing Lead Optimisation Development for launch Target Validation Lead Identification Candidate Drug (CD) Target Compound Patient 2nd Annual Technical Review, Brussels, 21 March 2006

  10. WP 6.1 Pharmainformatics Target Validation Using BMI ? Look for usage in patients of drug/compounds linked to targets in pathway Assess disease prevalence in patients - target validation 2nd Annual Technical Review, Brussels, 21 March 2006

  11. WP 6.1 Pharmainformatics Compartmentalised View of CRPS 2nd Annual Technical Review, Brussels, 21 March 2006

  12. WP 6.1 Pharmainformatics 2nd Annual Technical Review, Brussels, 21 March 2006

  13. WP 6.1 Pharmainformatics CRPS - Four Triggers - Same resulting pathology? Hettne, De Mos, Cases, de Bruijn, Mestres, Van Mulligen, Boyer, Van der Lei J. Am. Med. Inform. Assoc. submitted 2nd Annual Technical Review, Brussels, 21 March 2006

  14. WP 6.1 Pharmainformatics Journal of Cell Science 118, 4389-4392, 2005 2nd Annual Technical Review, Brussels, 21 March 2006

  15. WP 6.1 Pharmainformatics Assessment of NK-B Effectors In Patient Records Pathway-Driven Epidemiology Two drug classes evaluated 2nd Annual Technical Review, Brussels, 21 March 2006

  16. WP 6.1 Pharmainformatics • Next Steps: • Validation of patient population in IPCI database • New Case-Control studies • - Genetic polymorphisms in NF-kB regulation • - Preexisting viral infections • - Premorbidity medication use • - Comorbidity of disorders in which NF-kB plays a role • Can/should pathway-related information be encoded into the patient record? 2nd Annual Technical Review, Brussels, 21 March 2006

  17. WP 6.1 Pharmainformatics WP 6.1 - NHRs Information Continuum Pathology Pathway Target Ligand 2nd Annual Technical Review, Brussels, 21 March 2006

  18. WP 6.1 Pharmainformatics 2nd Annual Technical Review, Brussels, 21 March 2006

  19. WP 6.1 Pharmainformatics WP 6.1 - NHRs Information Continuum Clustering of Pathologies versus NHR Genes & Pathways using Text Mining Tools Pathology Pathway 2nd Annual Technical Review, Brussels, 21 March 2006

  20. WP 6.1 Pharmainformatics • Common Interests & Opportunities: • WP 6.2 • Pathway standards, formats and analysis • Pharmacological target identification, prioritisation, validation • Chemogenomics • WP 6.3 • Text Mining and Pathway Analysis • Chemogenomics 2nd Annual Technical Review, Brussels, 21 March 2006

  21. WP 6.1 Pharmainformatics Objectives • Establish a project that would: • Highlight the benefits of BMI in Drug Discovery  • Identify particular challenges of BMI  • Demonstrate the benefit of cross-functional collaboration  2nd Annual Technical Review, Brussels, 21 March 2006

More Related